Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 294 USD -0.18% Market Closed
Market Cap: 158B USD
Have any thoughts about
Amgen Inc?
Write Note

Operating Margin
Amgen Inc

19.2%
Current
32%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
19.2%
=
Operating Profit
6.2B
/
Revenue
32.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Amgen Inc
NASDAQ:AMGN
158B USD
19%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.9B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.1B EUR
-22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.3B USD
-9%
Country US
Market Cap 158B USD
Operating Margin
19%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.9B USD
Operating Margin
28%
Country US
Market Cap 119B USD
Operating Margin
40%
Country US
Market Cap 112.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.8B AUD
Operating Margin
26%
Country US
Market Cap 82.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.1B EUR
Operating Margin
-22%
Country US
Market Cap 32.3B USD
Operating Margin
-9%
No Stocks Found

Amgen Inc
Glance View

Market Cap
158B USD
Industry
Biotechnology

Amgen Inc., a leader in the biopharmaceutical industry, has spent over four decades revolutionizing the way we approach complex diseases. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen harnesses the power of human biology to develop innovative therapies for serious illnesses. Its robust portfolio features groundbreaking products that target diseases such as cancer, kidney disease, and rheumatoid arthritis. Notably, Amgen's flagship drugs, like Enbrel and Neulasta, have garnered significant market presence, contributing to the company’s solid financial performance. The firm’s commitment to research and development is underscored by its considerable investments in biotechnology, yielding a promising pipeline of future treatments that aim to improve patient lives while also providing strong returns for investors. As a powerhouse in the healthcare sector, Amgen stands out not just for its scientific advancements, but also for its strategic approach to growth. The company has embraced a culture of continuous improvement and collaboration, forming partnerships that enhance its market reach and innovation potential. With a focus on sustainable practices, Amgen is dedicated to ensuring that its operations are environmentally responsible while also delivering durable financial results. Its steady revenue growth and focus on shareholder return further bolster its profile as an attractive investment option. As healthcare demands evolve and an increasing global population seeks better treatments, Amgen is well-positioned to capitalize on these opportunities, making it a compelling choice for investors looking to navigate the dynamic biotech landscape.

AMGN Intrinsic Value
255.42 USD
Overvaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
19.2%
=
Operating Profit
6.2B
/
Revenue
32.5B
What is the Operating Margin of Amgen Inc?

Based on Amgen Inc's most recent financial statements, the company has Operating Margin of 19.2%.